QIAGEN to Acquire Nextal Biotechnologies
QIAGEN N.V. announced that it has entered into a definitive agreement to acquire Nextal biotechnology Inc., a fast-growing provider of proprietary sample preparation tools which make protein crystallization more accessible.
Nextal has developed and recently initiated the marketing of a comprehensive suite of consumables which dramatically simplify the process of sample preparation of proteins for subsequent crystallographic analysis. Despite having only recently been launched, Nextal's product sales are growing very rapidly and are already sold to leading academic institutes, biotechnology and major pharmaceutical companies. Like QIAGEN, Nextal has made significant moves towards the standardization of previously complex preanalytical processes within its own range of pre-manufactured consumables and is replacing homebrew methods.
Subject to the terms of the acquisition agreement, QIAGEN will pay approximately US$9.7 million in cash in exchange for all of the outstanding capital stock of Nextal. An additional consideration of approximately US$4.5 million is subject to certain milestones. QIAGEN expects to incur charges relating to the acquisition of less than US$1 million in its financial results for the second quarter of 2005. The Company anticipates the transaction will add approximately US$3 million in net sales and will be neutral to net income to QIAGEN's 2006 financial results.
The acquisition positions QIAGEN as a leading provider of an extensive portfolio of preanalytical solutions addressing structure determination, structure based drug design and structural genomics. This highly dynamic sector of the market is experiencing a period of rapid growth as it undergoes a tremendous increase in innovation and increased utility of its tools. In particular pharmaceutical companies use or intend to use these techniques throughout the drug discovery and development process
Other news from the department business & finance
These products might interest you

Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation

SepsiTest™-UMD CE IVD by Molzym
Make yourself independent: 16S/18S PCR for pathogen identification
Fast and precise detection of bacteria and fungi in blood/body fluids and tissue

SureSTART Vials and Well Plates by Thermo Fisher Scientific
SureSTART autosampler vials for all chromatography applications and budgets
3 performance level: Easily select products suited to your analytical, performance or value needs

Greener Alternative Products by Merck
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.